A lab technician sorts blood samples for COVID-19 vaccination study at the Research Centers of America in Hollywood, Florida. | Photographer: Chandan Khanna | AFP/Getty Images via Bloomberg
A lab technician sorts blood samples for COVID-19 vaccination study at the Research Centers of America in Hollywood, Florida. | Representational Image | Photographer: Chandan Khanna | AFP/Getty Images via Bloomberg
Text Size:

London: The University of Oxford and AstraZeneca Plc have restarted a U.K. trial of an experimental Covid-19 vaccine after the study was halted over concerns about a participant who fell ill.

Oxford said in a statement that the U.K. regulator, the Medicines Health Regulatory Authority (MHRA), had recommended that the trials resume after an independent review of the safety data triggered a pause on Sept. 6. It declined to disclose any details about the participant’s illness.

“The U.K. committee has concluded its investigations and recommended to the MHRA that trials in the U.K. are safe to resume,” AstraZeneca said.

While temporary halts are common in vaccine trials, the interruption to the closely watched Astra-Oxford study had raised concerns about the viability of one of the fastest-moving experimental shots seeking protection from the pandemic.

The statements from Astra and Oxford on Saturday didn’t say anything about the status of tests outside the U.K.

AstraZeneca’s Chief Executive Officer Pascal Soriot said on Thursday that an independent safety review board was reviewing whether the participant’s illness had been caused by the vaccine or was unrelated. Oxford said some 18,000 people have received “study vaccines” as part of the trials.

“We cannot disclose medical information about the illness for reasons of participant confidentiality,” it said. “We are committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.” – Bloomberg

 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And have just turned three.

At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrint’s future.

Support Our Journalism